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Introduction
Coronary artery bypass grafting (CABG) is amethod of choice
for revascularization in patientswithmultivessel disease and
diabetesmellitus (DM). Although arterial grafts are preferred
in selected scenarios, the common practice is to use left
internal thoracic artery (LITA) to bypass the left anterior
descending artery (LAD), and to place venous conduits to
other target vessels. An often chosen vascular graft, the great
saphenous vein (SV), offers decent durability and is easy to
harvest. SV graft occlusion may occur in up to 12% of cases
within the first 6 months, and as many as 3.4% may occlude
within first 2 to 3 weeks.1 SV harvesting dramatically
changes the vein’s environment with disruption of blood
flow in vasa vasorum, damage to the adventitia, hypoxia, and
hyponutrition of the vessel wall along with focal endothelial
disruption.2 Acute SV graft failure is usually a result of graft
thrombosiswhich, amongother factors, like technical failure,









Abstract Introduction Intraoperative thrombosis of saphenous veins (SV) during open harvest-
ing is very rare.
Case Report We present a case of a 60-year-old male patient with multivessel
coronary artery disease and a history of a non-ST elevation acute coronary syndrome,
and type-2 diabetes mellitus admitted for coronary artery bypass grafting, in whom
bilateral intraoperative SV thrombosis occurred during graft harvesting. Routine
thrombophilia screening showed no abnormalities and cancer was excluded. Com-
pared with healthy controls, we observed prolonged fibrin clot lysis time and increased
thrombin generation reflected by endogenous thrombin potential. Scanning electron
microscopy of the thrombosed material revealed compact and thick fibrin layer on the
clot surface with a solid mass of unusually compressed platelets and erythrocytes
underneath. The patient was tested for fibrinogen and factor (F) XIII polymorphisms,
and was found to be heterozygous for β-fibrinogen HaeIII (-455G> A) and FXIII
Val34Leu (100G> T).
Conclusion β-fibrinogen HaeIII and FXIII Val34Leu polymorphisms are reflected in
reduced clot permeability and susceptibility to lysis, and might contribute to intra-
operative SV thrombosis during vascular grafting procedures. Carriers of those are at
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A 60-year-old male patient with multivessel coronary artery
disease, who suffered from a non-ST elevation acute coronary
syndrome (NSTE-ACS) 1 month prior to admission, a non-
smoker with type-2 DM on metformin, peptic ulcer disease,
and a history of alcohol abuse, was admitted to our institution
for CABG. Just after the NSTE-ACS, a left ventricle (LV) throm-
bus was seen on one echocardiographic examination, but it
was absent during follow-up. There was no deep venous
thrombosis or bleeding diathesis history. On admission, the
patient was on aspirin 75mg (once daily) and enoxaparin
60mg (once daily). Routine laboratory tests were within
normal ranges (►Table 1). There were no abnormalities on
physical examination, apart from obesity (body mass index,
32.7 kg/m2) when the patient was admitted. The lower ex-
tremities appeared normal. There were no varicose veins, no
signs or symptoms of venous insufficiency, and the past
medical history was negative for both personal and family
history of chronic venous insufficiency or varicose veins. The
patient was operated on following the standard procedures.
During LITA harvest, a cardiac surgery resident harvested the
right SV using the open technique. The wall of the SV looked
grossly normal. Upon dissection, the side branches were tied
off and clipped, andaneedlewasplacedat thedistal end,while
theproximal endwasstill not separated. Anattemptwasmade
Table 1 Results of initial and follow-up laboratory testing
Variable Normal ranges Preoperative Postoperative day 6 Postoperative day 103
Coagulation tests
Red blood count (103/µL) 4.20–6.00 4.00 3.36 –
Hemoglobin (g/dL) 14.0–18.0 9.7 8.5 –
White blood count (103/µL) 3.80–10.00 7.19 6.55 –
Platelet count (103/µL) 140–440 296 287 –
APTT, s 25.9–36.6 30.2 28.2 –
PT (s) 10.4–13.0 12.3 11.4 –
PT (%) 82–121 86 99 –
INR <1.50 1.11 1.02 –
Platelet aggregation
0.5 mmol/L arachidonic acid, % – – 54 –
10 µmol/L ADP, % – – 52 –
Thrombophilia screening
Fibrinogen (g/L) 2.10–4.00 – 6.32 4.10
Antithrombin III (%) 79–112 – 89 89
D-dimer (µg/L) <500 – 1825 –
anti-Xa (IU/mL) – – 0.48 –
Homocysteine (µmol/L) 3–15 – 11.5 12.4
Protein C (%) 70–140 – 123 119
Protein S (%) 67–139 – 70 70
Factor VIII (%) 70–150 – 291 135
Leiden c.1601G> A – – GG (no mutation) GG (no mutation)
Prothrombin c.97G> A – – GG (no mutation) GG (no mutation)
β-fibrinogen -455G> A – – – GA (heterozygote)
Factor XIII 100G> T – – – GT (heterozygote)
Lupus anticoagulant ratio <1.20 – 1.06 0.86
Lupus anticoagulant ratio (APTT) <1.15 – 0.93 0.85
Anticardiolipin IgG 0–15 – 3.4 GPL 5.4 GPL
Anticardiolipin IgM 0–17 – 3.5 MPL 2.7 MPL
Anti-β-2-glycoprotein I IgG antibody 0.0–8.0 – 1.0 SGU 0.5 SGU
Anti-β-2-glycoprotein I IgM antibody 0.0–10.0  1.2 SMU 1.0 SMU
Abbreviations: APTT, activated partial thromboplastin time; GPL, IgG phospholipid unit; Ig, immunoglobulin; INR, international normalized ratio;
MPL, IgM phospholipid unit; PT, prothrombin time; SGU, standard IgG β-2 glycoprotein unit; SMU, standard IgM β-2 glycoprotein unit.
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to flush the vein with a solution containing blood (20mL),
heparin (15,000 IU), andnormal saline (10mL),while thedistal
end was closed with an atraumatic vascular clamp, and vein
thrombosiswas noted. Upon the separation of the distal end, a
luminal thrombuswasvisible. The left SVwas then takendown
using the same protocol by an experienced staff cardiac
surgeon,with the same result. Presence of a luminal thrombus
was confirmed upon separation of the proximal end. Systemic
heparin was administered, and normal LITA outflow was
confirmed. Concerns regarding safety of cardiopulmonary
bypass use were raised due to suspected thrombotic issue,
and the approach was modified. The LITA–LAD anastomosis
was completed off-pump on a beating heart.
The postoperative course was uneventful. On postopera-
tive day 1, the patient received dual antiplatelet therapywith
aspirin and clopidogrel and was discharged on day 6 with no
signs of thrombosis or myocardial ischemia. Elective angio-
plasty of nongrafted vessels was scheduled, and a complete
thrombophilia screening was done (►Table 1). On the 3- and
12-month follow-up, the patient did well.
Diagnostic Approach
Because a thrombophilia was suspected, screening was
initiated showing no abnormalities (►Table 1).
Cancer was excluded as a cause of thrombosis. Positive
antibodies against neutrophil cytoplasm antigens (pANCA
and cANCA) were excluded as a cause of vasculitis. We then
proceeded to analyze fibrin phenotype, using the previously
described methodology.3,4 Briefly, plasma fibrin clot perme-
ability was determined in a hydrostatic pressure system.
Tubes containing fibrin clots formed from adding 20 mmol/L
calcium chloride and 1 U/mL human thrombin (Sigma) to
citrated plasma, were connected through plastic tubing to a
buffer reservoir (0.05M Tris-HCl, 0.15M NaCl, pH 7.5). The
volume flowing through the gel was measured within
60minutes. A permeation coefficient (Ks), reflecting pore
size, was calculated from equation: Ks¼Q L η/t A Δp,
whereQ is theflow rate in time t, L is the length of a fibrin gel,
η is the viscosity of liquid,A is the cross section area, andΔp is
a differential pressure in dyne/cm2. Lower Ks values indicat-
ed reduced permeability. Fibrinogen was determined using
the Clauss method. Even though the follow-up fibrinogen
levelwas normal, we identified strongly decreased fibrin clot
permeability (Ks¼ 3.31 0.15 109cm2), compared with
healthy controls from our previous report (n¼ 30, Ks¼ 7.55
[7.00–7.96] 109cm23; samples collected during late follow-
up appointment on postoperative day 103). Compared with
healthy controls (n¼ 30) we observed prolonged clot lysis
time (CLT; 101 6 vs. 135 4.5minutes) and increased
thrombin generation reflected by endogenous thrombin
potential (ETP) in the studied subject (ETP¼ 1,138 134
vs. 1,463 87 nMmin, respectively); measurement of
the thrombin generation was done with calibrated automat-
ed thrombography (thrombinoscope BV, Maastricht, the
Netherlands) according to the manufacturer’s instructions
in the 96-well plate fluorometer (Ascent Reader, Thermo-
labsystems OY, Helsinki, Finland), equipped with the
390/460 filter set, at a temperature of 37°C. Briefly, 80
microliters of platelet-poor plasma were diluted with
20 µL of the reagent containing 5 pmol/L recombinant tissue
factor, 4 micromolar phosphatidylserine/phosphatidylcho-
line/phosphatidylethanolamine vesicle, and 20 µL of FluCa
solution (Hepes, pH7.35, 100 nmol/L CaCl2, 60mg/mLbovine
albumin, and 2.5 mmol/L Z-Gly-Gly-Arg-7-amino-4-meth-
ylcoumarin). Each plasma sample was analyzed in duplicate.
For analysis, the maximum concentration of thrombin gen-
erated was used.3
Cryosectioned tissue sections were fixed in ice-cold metha-
nol–acetone (1:1) mixture, peroxidase activity was quenched
with 3% H2O2 and unspecific background was blocked with 3%
bovine albumin (BSA, Sigma Co, St. Louis, Missouri, United
States). Primary adequate antibodies against fibrin or tissue
factor (TF) were applied (both Abcam, Cambridge, United
Kingdom). Primary antibodies were followed by the
corresponding secondary antibodies conjugated with fluoro-
chrome (Abcam) as previously described.5 Images were ana-
lyzed using Olympus BX 43 microscope. SVs immunostaining
revealed thick layer of fibrin directly on the vessel endothelium
(►Fig. 1A) andhighTF (►Fig. 1B) activity.Within the thrombus
we found abundant blood nuclear cells (nuclei stained using
DAPI) suggesting the presence of proinflammatory monocytes,
which are known source of TF. Unfortunately, wewere not able
to immunostain CD68 due to high unspecific background
resulting from large amounts offibrin. Themicroscopic analysis
showed abundant adventitial vessels (►Fig. 1C, D). Within
almost every single vessel, we found thrombi rich in both
prothrombin (►Fig. 1C) and TF (►Fig. 1D).
Prothrombotic fibrin clot phenotype reflected by reduced
Ks and prolonged CLT along with enhanced thrombin gener-
ation and unusual images obtained from the immuno-
staining of the SVs prompted us to perform analysis of
whole blood clot morphology using scanning electron mi-
croscopy (SEM), as previously described.6 After washing, the
thrombus was fixed with 2.5% glutaraldehyde phosphate
buffered saline solution. Specimens were dehydrated, gold
coated, and photographed digitally with a JEOL JSM 5410
(JEOL, Tokyo, Japan). The analysis revealed compact and thick
fibrin layer on the clot surface (►Fig. 1 E, F) with a solid mass
of unusually compressed platelets and erythrocytes under-
neath. This observation suggested very-high contractile
forces during clot formation in a platelet-driven, fibrin-
mediated mechanism of clot contraction, and prompted us
to study common fibrinogen and factor (F) XIII polymor-
phisms. The patient was heterozygous for β-fibrinogenHaeIII
(-455G>A) and FXIII Val34Leu (100G> T).
Discussion
A dramatic intraoperative SV thrombosis provoked by graft
harvesting for CABG lead to change in revascularization
strategy, but its cause remained unknown following the
standard thrombophilia screening. The cases of acute SV
graft thrombosis in the perioperative period are very rare,
and as few as 3% of grafts occlude within first 2 to
3 weeks.1,7
TH Open Vol. 4 No. 3/2020
Bilateral Saphenous Vein Thrombosis during CABG Mazur et al. e199
A normal SV is composed of the intima, themedia, and the
adventitia.8 The intima is built of the layer of endothelial cells
on the luminal side, the media consists of smooth muscle
cells, and the adventitia forms the outer part.8 In a normal
setting, the endothelium is crucial for vein integrity and
prevention of thrombosis,9 and its focal disruption may
predispose to vessel thrombosis.2 SV manipulation and
implantation leads to loss of endothelial integrity and elicits
an inflammatory response with platelet adhesion and leuko-
cyte recruitment. Notwithstanding, an overt thrombosis is
extremely rare in the operating room. SV dissection results in
blood flow disruption in vasa vasorum, and causes adventi-
tial damage, hypoxia, and vessel wall hyponutrition.10 Acute
perioperative saphenous vein graft failure is almost always a
result of graft thrombosis, but this very uncommonly occurs
prior to graft placement. Surgical factors, like technical
anastomotic failure or severe disproportion between the
target vessel and the graft, may lead to thrombosis, but
vessel injury and hypercoagulability are among potential
causes as well.11
Therewasnoevident inflammatoryprocess inmicroscopy in
our patient, but even if an inflammatory process was present
Fig. 1 Representative images of SV graft immunostaining after massive thrombosis (A–D) prothrombin stained red, TF stained green, nuclei
stained blue using DAPI and scanning electron microscopic images (E, F) of the surface of whole blood clot formed in vitro from citrated blood
obtained from the patient undergoing CABG. Box and arrow represent magnification of the fragment in the box. Arrows show pertinent stained
fragments (see text). CABG, Coronary artery bypass grafting; SV, saphenous veins; TF, tissue factor.
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preoperatively in our patient’s SVs, the inflammatory back-
ground alone could not explain the dramatic intraoperative
thrombosis. We hypothesized that increased thrombin genera-
tion and prothrombotic fibrin clot phenotypewere responsible
for the clinical presentation. Conversion of fibrinogen to fibrin
(facilitated by thrombin) is a concluding step of coagulation. It
has been shown that fibrin clots with small pores between
tightly packed thin fibrin fibers are relatively lysis resistant.12
Suchclotphenotypehasbeenevidenced inmultiple thrombotic
pathologies, such as myocardial infarction,6 ischemic stroke,13
and venous thromboembolism.4 The prothrombotic clot
phenotype, reflected by a tendency to form dense fibrin clots
resistant to lysis, has been previously reported in patients with
in-stent thrombosis.14 While routine thrombophilia screening
results in a high (almost 40%) detection rate of common
hypercoagulable states,15 there are prothrombotic conditions
thatescape routinediagnosticapproach. Theoverallmicroscop-
ic clot appearance and prothrombotic fibrin properties lead to
the discovery of two mutations in our patient that are not
routinely tested during thrombophilia screening, namely β-
fibrinogen -455G> A and FXIII100G> T.
Elevated fibrinogen was postulated as one of the risk
factors for early graft failure after CABG.11,16 Epidemiological
studies have established that elevated fibrinogen is strongly
associated with cardiovascular diseases.17 A 2005 meta-
analysis of individual records of 154,211 participants from
31 prospective studies revealed that age- and sex-adjusted
hazard ratio per 1 g/L increase in usual fibrinogen level for
coronary heart disease was 2.4 (95% confidence interval [CI]:
2.2–2.6), while for stroke, the hazard ratio was as high as 2.1
(95%CI: 1.8–2.3). Risk of coronary disease progression was
also linked to genetic polymorphisms of the fibrinogen gene.
De Maat et al found that A allele of β-fibrinogen -455G>A
was associated with more severe progression of coronary
disease, as documented angiographically.18 Gu and col-
leagues in a meta-analysis of 45 studies with 7,238 patients
found that A allele of the β-fibrinogen -455G>A is associat-
ed with susceptibility to coronary disease, and, also with
ischemic stroke (odds ratio for stroke¼ 1.5 [95% CI: 1.3–1.8]
for AAþGAvs. GG).19 In a recent study of patients with atrial
fibrillation, Hu and colleagues found that the A allele of β-
fibrinogen -455G> A was a risk factor for cardioembolic
stroke, probably by elevating the level of plasma fibrino-
gen.20 On the other hand, in a 2017 meta-analysis of 36
studies involving 26,940 cases and 34,694 controls, FXIII
Val34Leu polymorphism was shown to be associated with
risk myocardial infarction.21 FXIII is crucial to thrombus
stabilization, and changes of its plasma concentration reflect
nonspecifically the extent of thrombosis, as shown by Li et al
in a study on patients with cerebral venous thrombosis.22
Interesting associations of FXIII Val34Leu polymorphism and
thrombotic disorders have been reported. Jung et al reported
in a meta-analysis of 11 studies that FXIII Val34Leu poly-
morphism is associated with recurrent pregnancy loss.23
Although no association with the incidence of ischemic
stroke was found for this polymorphism,24 apparently
when the stroke occurs, Val34Leu polymorphism of FXIII
affects the severity of its outcome.25 Furthermore, Kreutz
and colleagues suggested in 2014 that FXIII Val34Leu poly-
morphism may increase risk of recurrent MI and death in
patients with angiographically established coronary artery
disease.26 In 2009, our group has shown in a study of 113
patients that in patients undergoing CABG FXIII Leu34 allele
is associated with decreased fibrin clot permeability and
efficiency of fibrinolysis.27
Conclusion
Our extensive workup showed that β-fibrinogen HaeIII and
FXIII Val34Leu polymorphisms are reflected in reduced clot
permeability and susceptibility to lysis. These mutations
likely contributed to intraoperative saphenous graft throm-
bosis. Further studies are needed to elucidate the role of
these polymorphisms in early graft failure after bypass
grafting procedures, however their contributory role seems
evident.
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